This Core Support Center Grant (P30) application requests continued support for an analytic and synthetic chemistry laboratory and administrative shared core infrastructure. The participating, currently funded, constituent projects continue research programs with human laboratory and treatment clinic studies of the clinical pharmacology of abused drugs, pharmacotherapies and other treatment strategies to treat drug abuse and addictions. Drugs of interest to participating projects and assays available include nicotine and its metabolites, cocaine, methamphetamine and other phenethylamines, alcohol, MDMA, ephedra alkaloids, caffeine, gamma hydroxybutyrate (GHB), salvinorin, adenosine, and neurosteroids, and opiates. Analytical methods have been developed and validated in the core analytic laboratory to support studies with these drugs. Other new assays and labeled (deuterated) compounds will be made available to the associated research projects as needed. Disciplines represented by the participating projects and investigators include psychiatry, clinical psychology, neurology, general internal medicine, cardiology and clinical pharmacology, psychopharmacology, toxicology, genetics, pediatrics, pharmacy, organic, medicinal and analytical chemistry, and statistics.
Our aims are: (1) to provide a state-of-the-art well equipped and staffed, analytical and synthetic chemistry laboratory resource for the participating projects of drug abuse researchers at UCSF and at other institutions. (2) To provide administrative support for manuscript preparation, IRB and related regulatory documents, grants management, and other research administrative services of value participating projects. (3) To provide statistical consulting services regarding study design and data analysis strategies, particularly optimal pharmacokinetic analysis to participating projects. The overall objective is to provide sophisticated analytic laboratory resources with stability of support together with adequate administrative support responsive to the needs of individual funded constituent scientific projects as those projects change and evolve. This facility is a cost-effective shared laboratory resource that enhances and extends research possibilities of investigators currently funded by NIH or other federal or nonfederal sources to further our understanding of human psychoactive drug use, abuse and addiction, its health consequences and its treatment management.

Public Health Relevance

When researching the causes of drug addictions, measuring the health and other consequences of drug use, and searching for effective treatments for addicted people, measures of the amount of drug actually in a person's body are often important. This grant supports a state of the art analytic chemistry laboratory that provides, to a large number of research groups, innovative, sensitive, reliable and cost effective measures of commonly used drugs like nicotine, methamphetamine, opiates and other addicting drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA012393-13
Application #
8288911
Study Section
Special Emphasis Panel (ZDA1-EXL-T (06))
Program Officer
Chiang, Nora
Project Start
1999-09-01
Project End
2015-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
13
Fiscal Year
2012
Total Cost
$608,690
Indirect Cost
$214,716
Name
University of California San Francisco
Department
Psychiatry
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Benowitz, Neal L; St Helen, Gideon; Dempsey, Delia A et al. (2016) Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity. Pharmacogenet Genomics 26:340-50
Rait, Michelle A; Prochaska, Judith J; Rubinstein, Mark L (2016) Reporting of cigar use among adolescent tobacco smokers. Addict Behav 53:206-9
St Helen, Gideon; Havel, Christopher; Dempsey, Delia A et al. (2016) Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. Addiction 111:535-44
Strasser, Andrew A; Souprountchouk, Valentina; Kaufmann, Amanda et al. (2016) Nicotine Replacement, Topography, and Smoking Phenotypes of E-cigarettes. Tob Regul Sci 2:352-362
Bahl, Vasundhra; Shim, Hyung Jun; Jacob 3rd, Peyton et al. (2016) Thirdhand smoke: Chemical dynamics, cytotoxicity, and genotoxicity in outdoor and indoor environments. Toxicol In Vitro 32:220-31
Nollen, Nicole L; Cox, Lisa Sanderson; Yu, Qing et al. (2016) A clinical trial to examine disparities in quitting between African-American and White adult smokers: Design, accrual, and baseline characteristics. Contemp Clin Trials 47:12-21
Northrup, Thomas F; Jacob 3rd, Peyton; Benowitz, Neal L et al. (2016) Thirdhand Smoke: State of the Science and a Call for Policy Expansion. Public Health Rep 131:233-8
Gubner, Noah R; Kozar-Konieczna, Aleksandra; Szoltysek-Boldys, Izabela et al. (2016) Cessation of alcohol consumption decreases rate of nicotine metabolism in male alcohol-dependent smokers. Drug Alcohol Depend 163:157-64
Northrup, Thomas F; Khan, Amir M; Jacob 3rd, Peyton et al. (2015) Thirdhand smoke contamination in hospital settings: assessing exposure risk for vulnerable paediatric patients. Tob Control :
Tanner, Julie-Anne; Novalen, Maria; Jatlow, Peter et al. (2015) Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation. Cancer Epidemiol Biomarkers Prev 24:1239-46

Showing the most recent 10 out of 161 publications